Production, Quality Control and Pharmacokinetic Studies of (166)Ho-EDTMP for Therapeutic Applications

(166)Ho-EDTMP is a major therapeutic agent which is widely used in bone palliation therapy. In this study, a (166)Ho-EDTMP complex was prepared successfully using an in-house synthesized EDTMP ligand and (166)HoCl(3). Ho-166 chloride was obtained by thermal neutron irradiation (1 × 10(13) ncm(−2)s(−...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahrami-Samani, Ali, Bagheri, Reza, Jalilian, Amir R., Shirvani-Arani, Simindokht, Ghannadi-Maragheh, Mohammad, Shamsaee, Mojtaba
Formato: Texto
Lenguaje:English
Publicado: Österreichische Apotheker-Verlagsgesellschaft 2010
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002809/
https://www.ncbi.nlm.nih.gov/pubmed/21179355
http://dx.doi.org/10.3797/scipharm.1004-21
Descripción
Sumario:(166)Ho-EDTMP is a major therapeutic agent which is widely used in bone palliation therapy. In this study, a (166)Ho-EDTMP complex was prepared successfully using an in-house synthesized EDTMP ligand and (166)HoCl(3). Ho-166 chloride was obtained by thermal neutron irradiation (1 × 10(13) ncm(−2)s(−1)) of natural Ho(NO(3))(3) samples (specific activity = 3–5 GBq/mg), dissolved in acidic media. The radiochemical purity of (166)Ho-EDTMP was checked by ITLC (>99%) and stability studies in presence of human serum and final preparation were performed. The biodistribution of (166)Ho-EDTMP and (166)HoCl(3) in wild-type rats was checked by scarification. SPECT imaging of (166)Ho-EDTMP was also performed in wild-type rats. A comparative accumulation study for (166)Ho-EDTMP and (166)HoCl(3) was performed for vital organs up to 48h. Significant bone accumulation (>70%) of the tracer in 48h was observed.

Ejemplares similares